Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF JUNE 05, 2020 SAM #6763
SOLICITATION NOTICE

A -- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

Notice Date

6/3/2020 2:07:41 PM
 

Notice Type

Solicitation
 

NAICS

541714 — Research and Development in Biotechnology (except Nanobiotechnology)
 

Contracting Office

ASPR OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE Washington DC 20201 USA
 

ZIP Code

20201
 

Solicitation Number

BARDABAA
 

Response Due

10/31/2020 12:00:00 AM
 

Archive Date

10/31/2020
 

Point of Contact

BARDA-BAA@hhs.gov, BARDA-BAA@hhs.gov
 

E-Mail Address

BARDA-BAA@hhs.gov, BARDA-BAA@hhs.gov
(BARDA-BAA@hhs.gov, BARDA-BAA@hhs.gov)
 

Description

We appreciate your interest in partnering with BARDA.� Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.� Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.� BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.� Thank you for understanding this unprecedented response and delays that will occur. The latest BARDA Broad Agency Announcement (BAA) is amendment 17 posted on June 3, 2020. Note: COVID-19 response related Areas of Interest includes: AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests [NEW] AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms AOI 8.3 COVID-19 Vaccine AOI 9.2 COVID-19 Therapeutics AOI 10 Respiratory protective devices AOI 17 Advanced Manufacturing Technologies All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 9.3 immunomodulators or therapeutics targeting lung repair, suspended AOI 9.5 Pre-exposure and post-exposure prophylaxis, suspended AOI 11 Ventilators, revised language for AOI 3 Antibacterials (submissions are placed in post COVID-19 review queue), added AOI 7.7.4, and revised language for AOI 9.2, 9.3, 9.5.�BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table. The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/e33b08d0e9e04e6faf2f84d5e25c1970/view)
 

Place of Performance

Address: Washington, DC 20515, USA

Zip Code: 20515

Country: USA
 

Record

SN05678478-F 20200605/200603230147 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |